Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Details : DUVAX is a Vaccine drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 26, 2025
Lead Product(s) : AV-1959R,AV-1980R
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : National Institutes of Health
Deal Size : $3.0 million
Deal Type : Funding
Duvax Alzheimer's Vaccine Wins $3M NIH Grant for U.S. Clinical Trials
Details : The funding aims to advance the clinical development of Duvax, the first dual-target. It is being evaluated for the treatment of Alzheimer Disease.
Product Name : Duvax
Product Type : Vaccine
Upfront Cash : Undisclosed
May 05, 2025
Lead Product(s) : AV-1959R,AV-1980R
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : National Institutes of Health
Deal Size : $3.0 million
Deal Type : Funding
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
Details : Undisclosed
Product Name : Abeta
Product Type : Vaccine
Upfront Cash : Inapplicable
February 18, 2025